• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

How BMS is Doing RBM (Risk-Based Monitoring)

Article

Pharmaceutical Executive

At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,

At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.

In this Applied Clinical Trials blog, Moe Alsumidale outlines the BMS’s RBM infrastructure.

Related Videos
Related Content